US Halts $500M Funding for 22 mRNA Vaccine Projects

The U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., has announced the termination of nearly $500 million in funding for 22 mRNA vaccine development projects, marking a significant shift in federal vaccine policy. Citing data that mRNA vaccines fail to effectively protect against upper respiratory infections like COVID-19 and flu, HHS plans to redirect funds towards broader and potentially safer vaccine platforms that remain effective as viruses mutate. Projects affected include collaborations with major companies such as Moderna, Pfizer, and institutions like Emory University, with some late-stage contracts allowed to continue to preserve prior investments. This decision has drawn sharp criticism from public health experts and vaccine specialists who warn that abandoning mRNA technology could undermine U.S. biosecurity and hinder preparedness for future pandemics. The move follows a broader pattern under Kennedy's leadership, including the controversial replacement of the U.S. Advisory Committee on Immunisation Practices with vaccine skeptics. Despite the criticism, HHS maintains the shift reflects a careful review of science and expert advice to prioritize vaccine platforms with stronger safety records and transparency.